CREATE MEDICINES
LIVE

Serial Number

99365272

Owner

Myeloid Therapeutics, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Aug 29, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CREATE MEDICINES Trademark

Serial Number: 99365272

CREATE MEDICINES is a trademark filed by Myeloid Therapeutics, Inc. on August 29, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Myeloid Therapeutics, Inc. (3 trademarks)

300 Technology Square, Suite 203
Cambridge, MA 02139

Entity Type: 03

CREATE MEDICINES, INC.

300 TECHNOLOGY SQUARE, SUITE 203
CAMBRIDGE, MA 02139

Entity Type: 03

Trademark Details

Filing Date

August 29, 2025

Registration Date

Not Registered

Published for Opposition

February 10, 2026

Goods & Services

Biological and medicinal preparations and substances for the prevention and treatment of oncological and immune system related diseases and disorders, and for use with transplantation; biological and medicinal preparations and substances for the prevention and treatment of fibrosis; biological and chemical products for use by clinicians in regenerative medicine for medical purposes, namely, cellular healing therapies and regenerative medicine; biological and medicinal preparations and substances for the prevention and treatment of cancer and infectious diseases; anti-cancer preparations; biological and medicinal preparations and substances for treating genetic diseases

Providing medical and scientific research information in the fields of cancer, oncology, autoimmune and infectious diseases, and transplantation; medical and scientific research services in the fields of the prevention and treatment of cancer, oncology, autoimmune and infectious diseases, and transplantation; medical and scientific research services in the fields of the prevention and treatment of fibrosis; medical and scientific research services in the field of regenerative medicine; research and development of regenerative medicine; medical and scientific research services in the field of genetic diseases and disorders; providing laboratory research services in the fields of cancer biology, cancer, oncology, autoimmune and infectious diseases, and transplantation

Medical services for the prevention and treatment of cancer and autoimmune and infectious diseases; medical services for the prevention and treatment of fibrosis; medical services in the field of regenerative medicine; medical services for the prevention and treatment of genetic diseases; providing information in the field of cancer, autoimmune and infectious diseases, fibrosis, and genetic diseases and disorders

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 7, 2026 NOAM
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 11, 2026 ASGN
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 17, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 17, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 17, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 17, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 17, 2026 CNEA
ASSIGNED TO EXAMINER
Jan 13, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 29, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 29, 2025 NWOS
NEW APPLICATION ENTERED
Aug 29, 2025 NWAP